TIME-HF
2026
Team based collaborative care model, facilitated by mHealth enabled and trained nurses, for management of heart failure with reduced ejection fraction in India (TIME-HF)
In 1,507 patients with HFrEF at 22 hospitals in India, nurse-led, app-supported collaborative care increased days alive and out of hospital over 2 years compared with usual care.
Resultado
Eficácia: Days alive and out of hospital (DAOH) during 2 years of follow-up (total follow-up time minus days in hospital and days from death to end of follow-up)OR 1,78 (IC 95% 1,42-2,23)
Abaixo de 1 a favor de usual care, acima de 1 a favor de nurse-led, app-supported collaborative care.
- Diferença absoluta
- 4,6 pontos
- NNT
- 22
A diferença absoluta e o NNT derivam das taxas de eventos.
Também relatado: All-cause death 163/755 (21.59%) vs 201/752 (26.73%); RR 0.80 (95% CI 0.67–0.97); adjusted Cox HR 0.78 (95% CI 0.63–0.95), P=0.028.
- Subtema
- Collaborative care model
- Desenho
- parallel-group, open-label, multicentre cluster-randomised controlled trial; 22 hospital units in India randomised 1:1 by computer-generated sequence (no blocking or matching) to intervention or usual care; about 70 patients per centre (≈770 per arm); rolling recruitment over 6–12 months; 2-year follow-up per patient
- Relevância
- Importante: um de vários pilares.
- Fonte
- Jeemon P, Ganapathi S, et al. Circulation. 2026; published online 30 August.doi 10.1161/circulationaha.126.082490
Discussão e crítica
Nothing new was prescribed here: a trained nurse, a phone app and structured counselling raised four-pillar therapy from 22% to 37% and bought days out of hospital and fewer deaths: the gap between what the guidelines say and what patients receive is itself treatable. Cluster-randomised and open-label, so the difference includes the attention the intervention arm received, and 22 units mean the unit of randomisation is small. Read as a health-services finding for a setting where 57% of patients live rurally; whether the same nurse-and-app package moves anything where baseline adherence is already high is a different trial.